Answers are grounded in this paper and cite their sources.
Randomized trial compares novel combinations with standard chemoimmunotherapy, suggesting improved outcomes in patients with advanced gastric cancer.
e16045 Background: For patients with unresectable HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma, first-line chemotherapy alone provides limited benefit. Combining novel agents—including immune checkpoint inhibitors (ICIs), adoptive cell therapy (ACT), and targeted therapies—with chemotherapy may improve outcomes. This network meta-analysis (PROSPERO: CRD420251058622) comprehensively compares the efficacy and safety of these emerging first-line regimens. Methods: We systematically searched PubMed, EMBASE, the Cochrane Library, and conference abstracts (Jan 2013–Aug 2025) for randomized controlled trials evaluating first-line systemic treatments. A frequentist random-effects network meta-analysis was performed to synthesize evidence on overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (TRAEs). Results: Twenty-nine trials (14,318 patients, 18 regimens) were included. ACT combined with triplet chemotherapy ranked highest for improving PFS (P-score: 0.94) and ORR (SUCRA: 91.1), and showed a significant OS benefit over doublet chemotherapy (HR 1.49, 95% CI 1.06–2.09). Adding a PD-1 inhibitor to doublet chemotherapy significantly improved both OS and PFS. Bispecific antibodies demonstrated considerable efficacy: PD-1/CTLA-4 bispecific antibody plus doublet chemotherapy ranked first for OS (P-score: 0.86) and third for PFS (P-score: 0.88); PD-L1/TGF-β bispecific antibody plus doublet chemotherapy ranked second for OS (P-score: 0.86) and third for ORR (SUCRA: 82.9). MET inhibitor plus triplet chemotherapy ranked second for PFS (P-score: 0.89) and ORR (SUCRA: 87.6) and third for OS (P-score: 0.86). Other targeted agents (anti-EGFR, anti-VEGF, TKIs) combined with chemotherapy did not confer significant survival advantages. All chemotherapy-based combinations increased the risk of grade ≥3 TRAEs versus doublet chemotherapy, with safety profiles consistent with known toxicity patterns and no new safety signals. Conclusions: Beyond standard chemoimmunotherapy, ACT-based combinations and bispecific antibody regimens show meaningful survival benefits with acceptable toxicity. This is the first network meta-analysis to evaluate the clinical applicability of ACT and bispecific antibodies in the first-line setting for advanced gastric cancer. These findings support the consideration of novel immunotherapeutic combinations and may inform future trial design.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: